HRP20241466T1 - Mutirani glikoprotein virusa vezikularnog stomatitisa - Google Patents
Mutirani glikoprotein virusa vezikularnog stomatitisa Download PDFInfo
- Publication number
- HRP20241466T1 HRP20241466T1 HRP20241466TT HRP20241466T HRP20241466T1 HR P20241466 T1 HRP20241466 T1 HR P20241466T1 HR P20241466T T HRP20241466T T HR P20241466TT HR P20241466 T HRP20241466 T HR P20241466T HR P20241466 T1 HRP20241466 T1 HR P20241466T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- protein
- seq
- sequence
- cell
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 241000711975 Vesicular stomatitis virus Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 25
- 150000001413 amino acids Chemical class 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 230000034217 membrane fusion Effects 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 108020004084 membrane receptors Proteins 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306255 | 2017-09-22 | ||
| PCT/EP2018/075824 WO2019057974A1 (en) | 2017-09-22 | 2018-09-24 | GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS |
| EP18773448.8A EP3684786B1 (en) | 2017-09-22 | 2018-09-24 | Mutated glycoprotein of vesicular stomatitis virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241466T1 true HRP20241466T1 (hr) | 2025-01-03 |
Family
ID=60153233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241466TT HRP20241466T1 (hr) | 2017-09-22 | 2018-09-24 | Mutirani glikoprotein virusa vezikularnog stomatitisa |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US12091434B2 (enExample) |
| EP (3) | EP4442816A3 (enExample) |
| JP (2) | JP2020534007A (enExample) |
| CA (1) | CA3076094A1 (enExample) |
| DK (1) | DK3684786T3 (enExample) |
| ES (1) | ES2991089T3 (enExample) |
| FI (1) | FI3684786T3 (enExample) |
| HR (1) | HRP20241466T1 (enExample) |
| HU (1) | HUE069207T2 (enExample) |
| LT (1) | LT3684786T (enExample) |
| PL (1) | PL3684786T3 (enExample) |
| PT (1) | PT3684786T (enExample) |
| SI (1) | SI3684786T1 (enExample) |
| WO (1) | WO2019057974A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3684786T3 (da) | 2017-09-22 | 2024-10-28 | Centre Nat Rech Scient | Muteret glycoprotein af vesikulær stomatitisvirus |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
| SG11202112344VA (en) | 2019-05-23 | 2021-12-30 | Massachusetts Inst Technology | Ligand discovery and gene delivery via retroviral surface display |
| EP4013459B1 (en) * | 2019-08-16 | 2025-07-23 | Mayo Foundation for Medical Education and Research | Chimeric vesiculoviruses and methods of use |
| CN115397838A (zh) * | 2020-01-10 | 2022-11-25 | 卡罗根公司 | 溶瘤病毒样囊泡的组合物和使用方法 |
| CN115768784A (zh) * | 2020-02-06 | 2023-03-07 | 勃林格殷格翰动物保健有限公司 | 用于检测抗弹状病毒抗体的多肽 |
| WO2022013872A1 (en) * | 2020-07-14 | 2022-01-20 | Ichilov Tech Ltd. | Pseudotyped viruses configured to express car in t-cells |
| CA3206009A1 (en) | 2021-01-27 | 2022-08-04 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| CN112852757A (zh) * | 2021-02-01 | 2021-05-28 | 南京大学 | 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法 |
| CA3212006A1 (en) | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| EP4323381A1 (en) * | 2021-04-16 | 2024-02-21 | Massachusetts Institute of Technology | Viral targeting of hematopoietic stem cells |
| US20250027073A1 (en) * | 2021-12-06 | 2025-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| IL291148A (en) * | 2022-03-06 | 2023-10-01 | Noga Therapeutics Ltd | Lentiviral vectors for in vivo targeting of hematopoietic cells |
| IL316839A (en) | 2022-05-17 | 2025-01-01 | Umoja Biopharma Inc | Production of viral particles |
| TW202409288A (zh) | 2022-07-25 | 2024-03-01 | 美商英特瑞斯生物療法公司 | 突變多肽、包含該等突變多肽之組合物及其用途 |
| WO2024050450A1 (en) | 2022-08-31 | 2024-03-07 | Gigamune, Inc. | Engineered enveloped vectors and methods of use thereof |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| IL320495A (en) | 2022-11-04 | 2025-06-01 | Umoja Biopharma Inc | Construction of polynucleotide vectors and related viral methods |
| CN120457212A (zh) | 2022-11-04 | 2025-08-08 | 优莫佳生物制药股份有限公司 | 展示融合分子的慢病毒颗粒及其用途 |
| CN120936364A (zh) | 2023-01-27 | 2025-11-11 | 瑞泽恩制药公司 | 修饰的弹状病毒糖蛋白及其用途 |
| WO2024196738A2 (en) * | 2023-03-17 | 2024-09-26 | Kelonia Therapeutics, Inc. | In vivo daric |
| WO2024213019A1 (zh) * | 2023-04-10 | 2024-10-17 | 深圳市济因生物科技有限公司 | 突变型vsvg及靶向载体 |
| WO2024216227A1 (en) | 2023-04-12 | 2024-10-17 | Vyriad | Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof |
| WO2024238153A1 (en) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| WO2025006882A1 (en) * | 2023-06-30 | 2025-01-02 | The Children's Hospital Of Philadelphia | Click chemistry assisted cell surface engineering for restoring lentivirus entry |
| WO2025017052A1 (en) * | 2023-07-18 | 2025-01-23 | Vivebiotech S.L. | Purification resin and methods for using the same |
| TW202521554A (zh) * | 2023-08-11 | 2025-06-01 | 美商克隆尼亞治療股份有限公司 | 用於修飾細胞的組成物 |
| WO2025036498A1 (zh) * | 2023-08-16 | 2025-02-20 | 深圳市济因生物科技有限公司 | 一种病毒载体及其在感染b细胞中的应用 |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US12269882B1 (en) | 2023-09-25 | 2025-04-08 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025072615A1 (en) | 2023-09-29 | 2025-04-03 | Orbital Therapeutics, Inc. | Improved methods of making rna by splinted ligation and compositions thereof |
| WO2025102013A1 (en) | 2023-11-10 | 2025-05-15 | Vyriad | Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof |
| WO2025162379A1 (zh) * | 2024-02-01 | 2025-08-07 | 深圳市济因生物科技有限公司 | 一种多肽及包含所述多肽基因的病毒载体 |
| WO2025189142A1 (en) | 2024-03-08 | 2025-09-12 | Vyriad | Membraned vesicles and purification methods thereof |
| WO2025212851A2 (en) | 2024-04-03 | 2025-10-09 | Orbital Therapeutics, Inc. | mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025260074A1 (en) | 2024-06-14 | 2025-12-18 | Vyriad | Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles |
| WO2025259931A1 (en) | 2024-06-14 | 2025-12-18 | Orbital Therapeutics, Inc. | Compositions and methods for rna circularization |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1716858B9 (en) * | 1999-09-17 | 2009-08-12 | Wellstat Biologics Corporation | Oncolytic virus |
| NZ534310A (en) * | 2002-02-07 | 2008-03-28 | Novozymes Delta Ltd | Albumin-fused anti-angiogenesis peptides |
| JP4411523B2 (ja) * | 2004-03-04 | 2010-02-10 | 株式会社日健総本社 | 抗ウイルス剤 |
| US8008268B2 (en) * | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
| PT2020444T (pt) * | 2007-08-03 | 2017-08-29 | Pasteur Institut | Vetores de transferência lentivirais deficientes não integrativos para vacinas |
| EP2185192B1 (en) * | 2007-08-03 | 2018-10-31 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| RU2705244C2 (ru) * | 2012-12-12 | 2019-11-06 | Тёрнстоун Лимитед Партнершип | Композиции и способы лечения рака мозга |
| DK3684786T3 (da) | 2017-09-22 | 2024-10-28 | Centre Nat Rech Scient | Muteret glycoprotein af vesikulær stomatitisvirus |
-
2018
- 2018-09-24 DK DK18773448.8T patent/DK3684786T3/da active
- 2018-09-24 HU HUE18773448A patent/HUE069207T2/hu unknown
- 2018-09-24 LT LTEPPCT/EP2018/075824T patent/LT3684786T/lt unknown
- 2018-09-24 ES ES18773448T patent/ES2991089T3/es active Active
- 2018-09-24 FI FIEP18773448.8T patent/FI3684786T3/fi active
- 2018-09-24 HR HRP20241466TT patent/HRP20241466T1/hr unknown
- 2018-09-24 WO PCT/EP2018/075824 patent/WO2019057974A1/en not_active Ceased
- 2018-09-24 US US16/649,271 patent/US12091434B2/en active Active
- 2018-09-24 PL PL18773448.8T patent/PL3684786T3/pl unknown
- 2018-09-24 PT PT187734488T patent/PT3684786T/pt unknown
- 2018-09-24 JP JP2020516534A patent/JP2020534007A/ja active Pending
- 2018-09-24 EP EP24192413.3A patent/EP4442816A3/en active Pending
- 2018-09-24 SI SI201831168T patent/SI3684786T1/sl unknown
- 2018-09-24 CA CA3076094A patent/CA3076094A1/en active Pending
- 2018-09-24 EP EP24192417.4A patent/EP4446337A3/en active Pending
- 2018-09-24 EP EP18773448.8A patent/EP3684786B1/en active Active
-
2023
- 2023-08-28 JP JP2023138247A patent/JP2023179436A/ja active Pending
- 2023-09-25 US US18/473,720 patent/US12030915B2/en active Active
-
2024
- 2024-04-08 US US18/629,579 patent/US12291551B2/en active Active
- 2024-04-08 US US18/629,466 patent/US12297237B2/en active Active
- 2024-04-08 US US18/629,504 patent/US12264180B2/en active Active
- 2024-04-08 US US18/629,097 patent/US12269848B2/en active Active
-
2025
- 2025-02-14 US US19/053,808 patent/US12410216B2/en active Active
- 2025-02-14 US US19/053,784 patent/US12410215B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241466T1 (hr) | Mutirani glikoprotein virusa vezikularnog stomatitisa | |
| Mulder et al. | Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides | |
| JP5911481B2 (ja) | 抗癌性融合タンパク質 | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| MX2019015502A (es) | L-asparaginasa modificada. | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| JP2015501156A5 (enExample) | ||
| JP2017514522A5 (enExample) | ||
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof | |
| EA201990856A1 (ru) | Новые противомикробные агенты против бактерий enterococcus | |
| NZ724196A (en) | Uti fusion proteins | |
| EP2692353A3 (en) | Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis | |
| PH12018500468A1 (en) | Fusion protein | |
| US20230027819A1 (en) | Cell-penetrating peptide dimers, method for preparing the same, and cargo delivery system using the same | |
| WO2019152418A3 (en) | Anti-inflammatory compounds and methods of use | |
| KR102166543B1 (ko) | 켈로이드 억제용 조성물 및 그 억제 방법 | |
| HRP20211962T1 (hr) | Krnji glikoprotein g virusa herpes simplex 2 | |
| KR20190072602A (ko) | Protransducine-C: 유전자 도입 활성제 | |
| NZ745944B2 (en) | Fusion proteins of pd-1 and 4-1bb | |
| NZ740555B2 (en) | Fusion protein | |
| HK1250939A1 (zh) | 针对rsv的疫苗 |